Comprehensive Evidence-Based Assessment and Prioritization of Potential Antidiabetic Medicinal Plants:  A Case Study from Canadian Eastern James Bay Cree Traditional Medicine by Haddad, Pierre S. et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 893426, 14 pages
doi:10.1155/2012/893426
Review Article
ComprehensiveEvidence-BasedAssessmentand
Prioritization of Potential Antidiabetic Medicinal Plants:
ACase StudyfromCanadian Eastern JamesBay Cree
TraditionalMedicine
Pierre S. Haddad,1,2 Lina Musallam,1,2 Louis C. Martineau,1 Cory Harris,1,3 Louis Lavoie,1
John T. Arnason,1,4 Brian Foster,1,5 Steffany Bennett,1,6 Timothy Johns,1,3 Alain Cuerrier,1,7
EmmaCoonCome,8 ReneCoonCome,8 JosephineDiamond,9 LouiseEtapp,8 CharlieEtapp,8
Jimmy George,10 CharlotteHuskySwallow,8 Johnny HuskySwallow,8 Mary Jolly,11
Andrew Kawapit,10 ElizaMamianskum,10 John Petagumskum,10 SmalleyPetawabano,8
LauriePetawabano,8 AlexWeistche,9 andAlaaBadawi12
1 Canadian Institutes of Health Research Team in Aboriginal Antidiabetic Medicines, Montreal, QC, Canada H3C 317
2 Department of Pharmacology, Universit´ ed eM o n t r ´ eal and Montreal Diabetes Research Center, P.O. Box 6128,
Downtown Postal Station, Montreal, QC, Canada H3C 3J7
3 School of Dietetics and Human Nutrition and Center for Indigenous Peoples’ Nutrition and Environment, McGill University,
Sainte-Anne-de-Bellevue, QC, Canada H9X 3V9
4 Department of Biology, University of Ottawa, Ottawa, ON, Canada K1N 6N5
5 Department of Cellular and Molecular Medicine, University of Ottawa and Therapeutic Products Directorate, Health Canada,
Ottawa, ON, Canada K1A 1B6
6 Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada K1H 8M5
7 Plant Biology Research Institute, Universit´ ed eM o n t r ´ eal and Montreal Botanical Garden, Montreal, QC, Canada H1X 2B2
8 Cree Nation of Mistissini, Eeyou Istchii, QC, Canada GOW 1CO
9 The Crees of Waskaganish First Nation, Eeyou Istchii, QC, Canada JON 1RO
10Whapmagoostui First Nation, Eeyou Istchii, QC, Canada JOM 1GO
11Cree Nation of Nemaska, Nemaska, QC, Canada JLY 3BO
12Oﬃce of Biotechnology, Genomics, and Population Health, Public Health Agency of Canada, Toronto, ON, Canada M5V 3L7
Correspondence should be addressed to Pierre S. Haddad, pierre.haddad@umontreal.ca
Received 18 May 2011; Accepted 9 September 2011
Academic Editor: Arndt B¨ ussing
Copyright © 2012 Pierre S. Haddad et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Canadian Aboriginals, like others globally, suﬀer from disproportionately high rates of diabetes. A comprehensive evidence-based
approachwasthereforedevelopedtostudypotentialantidiabeticmedicinalplantsstemmingfromCanadianAboriginalTraditional
Medicine to provide culturally adapted complementary and alternative treatment options. Key elements of pathophysiology of
diabetes and of related contemporary drug therapy are presented to highlight relevant cellular and molecular targets for medicinal
plants. Potential antidiabetic plants were identiﬁed using a novel ethnobotanical method based on a set of diabetes symptoms. The
most promising species were screened for primary (glucose-lowering) and secondary (toxicity, drug interactions, complications)
antidiabetic activity by using a comprehensive platform of in vitro cell-based and cell-free bioassays. The most active species
were studied further for their mechanism of action and their active principles identiﬁed though bioassay-guided fractionation.
Biological activity of key species was conﬁrmed in animal models of diabetes. These in vitro and in vivo ﬁndings are the basis for
evidence-based prioritization of antidiabetic plants. In parallel, plants were also prioritized by Cree Elders and healers according
to their Traditional Medicine paradigm. This case study highlights the convergence of modern science and Traditional Medicine
while providing a model that can be adapted to other Aboriginal realities worldwide.2 Evidence-Based Complementary and Alternative Medicine
1.Background onDiabetes
Diabetesisachronicmetabolicdiseasethatarisesfromadys-
function in the body’s production of the anabolic hormone
insulin, a reduction of the response of peripheral organs to
the same hormone, or both [1–3]. There exist two predomi-
nant types of the disease; namely, type 1 diabetes (T1D) and
type 2 diabetes (T2D) [2, 4, 5]. The former often aﬀects
younger individuals and is related to autoimmune respons-
esagainstinsulinorothercomponentsrelatedtoinsulinpro-
duction that lead to the destruction or severe dysfunction
of pancreatic beta cells [2, 4, 5]. Thus, T1D is characterized
by insulin insuﬃciency and is treated by exogenous insulin
administration, hence, its former deﬁnition as an insulin-de-
pendentttypeofdiabetes.Incontrast,thepathophysiological
scheme that is generally considered by the contemporary
scientiﬁc community to explain T2D begins with a gradual
attenuation in the response of tissues to insulin, called
insulin resistance [2, 4–6]. Pancreatic beta cells that produce
the hormone compensate by increasing insulin secretion in
response to a given rise in circulating glucose. Eventually,
the pancreas decompensates, in good part because of a
signiﬁcant loss in the functional mass of beta cells. This leads
to a frank deregulation of blood glucose whereby it remains
chronically elevated.
Clinically, the initial phases of the disease are asymp-
tomatic. Indeed, the state ofinsulin resistance is usuallyasso-
ciated with a normal fasting blood glucose (FBG) concentra-
tion [7]. However, two elements can help identify this state,
namelyimpairedglucosetolerance(IGT)andhyperinsuline-
mia [2, 7, 8]. The former can express itself as a blood glucose
concentration that reaches beyond 11mM after a meal or
after an oral glucose challenge called oral glucose toler-
ance test (OGTT). For its part, hyperinsulinemia is related to
the aforementioned pancreatic compensation [9]. After pan-
creatic decompensation, blood glucose remains chronically
elevated, as evidenced by fasting hyperglycemia. In fact, it is
important at this point to highlight that T2D is a metabolic
disease that involves not only the deregulation of glucose
homeostasis, but also that of lipids [10]. Indeed, elevated
free fatty acids in circulation and the excessive deposition
of lipids in abdominal fat or in ectopic sites, such as the
skeletal muscle and liver, are recognized as key elements in
the development of insulin resistance [11–14].
However, individuals suﬀering from T2D do not gener-
allysuccumbtotheactualhyperglycemiaordyslipidemiabut
to their consequences. For instance, it is through a process,
coined glucolipotoxicity, that the pancreas is believed to lose
its functional mass of beta cells [15]. Elevated blood glucose
and lipids also cause micro- and macrovascular lesions. The
former aﬀects principally the kidney (diabetic nephropathy),
peripheral nerves (diabetic neuropathy), and the retina (dia-
betic retinopathy). Macrovascular lesions, for their part, lead
to cardiovascular disease. T2D is also associated with a state
of oxidative stress and chronic low-grade inﬂammation [16–
18]. Finally, several factors, including diabetic neuropathy
(loss of sensation and hence increased risk of wounds to
the extremities), poor circulation, and a weakened immune
response, are at the root of the preponderance of slow-
healing wounds in T2D [19, 20]. It is therefore not entirely
surprising that T2D is the leading cause of nontraumatic
limb amputation, of blindness, of renal hemodialysis, and
of cardiovascular disease [7]. Taken altogether, it is these
complicationsofdiabetesthatcausethehighlevelofmorbid-
ity and mortality related to this metabolic disease.
T2D actually represents the pathological endpoint of a
cluster of metabolic disturbances that are called metabolic
syndrome, syndrome X, or insulin resistance syndrome.
There exist several deﬁnitions put forth by various national
and international agencies but all include a combination
of the following factors [7, 21–24]: abdominal obesity,
dyslipidemia (notably including increased triglyceridemia,
low HDL-cholesterol, and high LDL-cholesterol), IGT,
hyperinsulinemia, and hypertension. A cluster of three or
more of these factors is necessary for the “diagnosis” of
metabolic syndrome. In particular, obesity is the leading
risk factor for T2D [25]. With the industrial and food sci-
ence revolutions of the previous century, most populations
around the globe have signiﬁcantly reduced their physical
activity and/or increased their intake of more processed,
energy-dense foods. Hence, metabolic diseases have arisen
as a result of chronic imbalances between energy intake
and energy expenditure. Notwithstanding genetic and other
environmental factors (such as stress, pollution, smoking),
T2D can rather eﬃciently be prevented and even treated
(notably in its initial stages) by lifestyle interventions [26–
28]. However, such changes are diﬃcult to put in place
and especially to establish in a persistent manner. Therefore,
several therapeutic interventions, mostly centered on phar-
maceutical drug therapy, have been developed to prevent
or improve the cluster of disorders described above. These
are summarized in the following section because they also
reﬂect the relevant targets for medicinal plants stemming
from Canadian Aboriginal Traditional Medicine that are the
focus of the present paper.
2. Contemporary Drug Therapy for T2D
According to the Canadian Diabetes Association Clinical
PracticeGuidelines[8,29],anewlydiagnosedtype2diabetic
willbeprescribeduptoﬁvediﬀerentdrugs.Theseinclude(1)
oral hypoglycemic drugs, alone or in combination, to reduce
blood sugar; (2) lipid-lowering drugs, especially to reduce
LDL-cholesterol; (3) antihypertensive drugs to reduce blood
pressure or prevent hypertension; (4) low-dose aspirin to
reduce the risk of thrombosis; (5) insulin, in more advanced
stages of the disease. The oral hypoglycemic drugs contain
several classes that point to the various targets that can be
usefulinrestoringglucosehomeostasis.Thisisalsopertinent
inthecontextofthepresentcasestudysincethesetargetsalso
represent the major cell bioassays used to screen medicinal
plant preparations for antidiabetic activity.
One of the oldest classes of oral hypoglycemic drugs is
represented by the insulin secretagogues, sulfonylureas [30].
These drugs target inward-rectifying potassium channels on
themembraneofpancreaticbetacellsthatareinvolvedintheEvidence-Based Complementary and Alternative Medicine 3
control of insulin secretion in response to increases in cir-
culating glucose [31, 32]. These drugs have two major limi-
tions. Firstly they confer a risk of hypoglycemia by virtue of
the robust insulin secretion they may trigger. Secondly, in
view of the aforementioned compensatory mechanisms, sul-
fonylureas may in fact act to precipitate pancreatic decom-
pensation.
Perhapsthemostcommonlyusedoralhypoglycemicsare
the biguanides, of which metformin is the predominant ex-
ample [33]. Biguanides were derived from compounds iso-
lated from the French lilac, Galega oﬃcinalis,ap l a n tl o n g
known to be indicated for symptoms of T2D [34, 35]. Met-
formin has grown to become the drug of ﬁrst choice in dia-
betes management worldwide [36], whereas earlier deriva-
tives such as phenformin had to be withdrawn because of
life-threatening side eﬀects [37].
It is now known that metformin targets AMP kinase
(AMPK), a metabolic master switch enzyme involved in in-
sulin-independent mechanisms that lead to enhanced glu-
coseuptakeinskeletalmuscleandtoreducedhepaticglucose
production [38, 39]. Both actions contribute to improving
insulin sensitivity and glucose homeostasis (discussed fur-
ther below).
Thiazolidinediones (TZDs), also known as glitazones,
represent a third class of oral hypoglycemic agents that target
the nuclear receptor/transcription factor PPARγ, principally
in adipose tissue. PPARγ modulates the expression of several
genes whose products control both the diﬀerentiation of
adipocytes and major enzymes involved in lipid homeostasis
[40–42].Inexperimentalandclinicalsettings,TZDsdecrease
insulin resistance, in part through their eﬀect of decreasing
the ratio of leptin to adiponectin, which are two important
adipokines involved in appetite control and insulin sensitiv-
ity, respectively [40, 43, 44]. Limitations to their use include
hepatic and cardiovascular side eﬀects that have forced the
withdrawalofsomemembersofthisclassfromtheAmerican
and European markets [45]. Less dramatic is the weight
gain/water retention that TZDs induce.
Alpha-glucosidase inhibitors act on enzymes of the intes-
tinal epithelial lining involved in the digestion of complex
sugars into smaller easily absorbed monosaccharides [46].
They can be used alone or in combination therapy, notably
to reduce postprandial hyperglycemia. However, they exhibit
dose-dependent gastrointestinal side eﬀects such as ﬂatu-
lence and diarrhea that can limit their use [47, 48].
The newest class of hypoglycemic drugs relates to the in-
cretins, gastrointestinal peptide hormones that act principal-
lyonbetapancreaticcells.Incretins,ofwhichGLP-1andGIP
arethepredominantspecies,delaygastricemptying, increase
glucose-induced insulin secretion, and stimulate beta cell
proliferation [49–51]. The latter eﬀect holds promise to
counter the gradually failing pancreatic functional mass
characteristic of T2D. Incretins are secreted by intestinal
cells and are rapidly degraded by dipeptidylpeptidase IV
(DPP-4) enzymes in the blood. Two types of drugs have
thus far been developed: the ﬁrst is degradation-resistant in-
cretin mimetics such as exenatide and the second is DPP-4
inhibitors [51]. Exenatide must be injected subcutaneously
and can cause nausea and diarrhea whereas hypersensitivity
reactions have been reported for DPP-4 inhibitors.
3.AboriginalDiabetesand
TraditionalMedicine
Canadian Aboriginals, like several of their counterparts
around the globe, exhibit a greater incidence of T2D than
their non-Aboriginal peers. This has been related to genetic
predisposition and the rapid change in lifestyle [52, 53]
movingcloserto“western”modelsandawayfromtraditional
behavior, notably traditional food and transportation. In
the Cree of Eeyou Istchee (CEI-Eastern James Bay area of
Northern Quebec), for instance, the age-adjusted prevalence
of T2D is 3- to 5-fold that of non-Aboriginal Quebecers,
with an average that reached 29% of the adult population
aged 20 years and older in 2009 [54]. This alarming rate of
T2D is confounded by the cultural disconnect of the modern
pharmaceutical therapies described above. CEI diabetics also
suﬀer from a much greater prevalence of a number of
diabetes complications [55–57].
In an eﬀort to identify more culturally relevant ap-
proaches to diabetes care, the CIHR Team in Aboriginal
Antidiabetic Medicines (CIHR-TAAM) was instated in 2003.
Its initial objective was to make the proof of concept that
therapeutic approaches based on Cree Traditional Medicine
(TM) held promising antidiabetic potential. As with many
Aboriginal cosmologies, Cree TM uses a holistic approach
whereby physical, mental, emotional, and spiritual compo-
nents of the “patient” need to be equilibrated. Medicinal
plants play an important role in this paradigm, and the
CIHR-TAAM has concentrated on providing the scientiﬁc
evidence base for their antidiabetic potential. Out of respect
for the other sacred aspects of Cree healing ways and because
the latter are less amenable to conventional scientiﬁc study,
the CIHR-TAAM has not addressed these issues directly.
An ethnobotanical approach was used to identify medicinal
plants based on a set of symptoms related to diabetes (dis-
cussed further below). Species with the greatest antidiabetic
potentialwerethenscreenedusingacomprehensiveplatform
of cell-based and cell-free in vitro bioassays as well as in vivo
animal models of obesity and diabetes, as detailed in the
following section.
Figure 1showstheﬂowchartoftheproject.Afterethnob-
otanical identiﬁcation and bioassay-based screening (tier
1), the species exhibiting promising biological activities are
takentothenextlevelwheremoredetailedstudiesarecarried
out to understand their cellular and molecular mode of
action, to identify their active phytochemical principles, and
to ascertain their safety and eﬃcacy using in vivo animal
studies (tier 2). The most active species are then taken to
the next level where they are tested in clinical studies with
Cree diabetics taking TM alongside the conventional drug
therapy (tier 3). Actually, because of the fact that Cree TM
has been used for centuries and that several Cree diabetics
have decided to call upon Cree Healing Ways, observational
clinical studies have begun in parallel with the more detailed
laboratory studies mentioned (tier 2). Notwithstanding this
particular situation, the following sections will detail the4 Evidence-Based Complementary and Alternative Medicine
Ethnobotanical study
(4 communities)
Collection of 17 species
(potentially antidiabetic)
Preparation of the extracts
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Clinical studies
Mechanisms
of action
Standardized plant extracts
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Toxicology
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The active
species
Standardization
In vitro assays
In vivo
validation
Figure 1: Project ﬂowchart.
scientiﬁc approach taken to provide the evidence base for
the antidiabetic activity of the Cree medicinal plants and the
protocoltakentoprioritizethem.Moreover,weundertookto
compare this outcome with the prioritization based on Cree
TM and cosmology.
4. Comprehensive Platform of In Vitro
BioassaysandIn Vivo Animal Models of
ObesityandT2D
T2D is a multifaceted, multiorgan metabolic disorder, as is
indirectly alluded to by the various targets of oral hypo-
glycemic drugs. Therefore, a platform of in vitro bioassays
was put in place to screen for primary and secondary
antidiabeticbiologicalactivities(Figure 2).Primaryactivities
refer to those observed on cells producing (pancreas) or re-
sponding (muscle, liver, adipose tissue) to insulin, or in-
volved in glucose absorption from the intestine. What we
termed “secondary antidiabetic biological activities” refer to
general parameters such as oxidative stress and inﬂamma-
tion, to parameters related to the complications of diabetes,
or to the assessment of potential toxicity or herb-drug
interactions (Figure 2).
4.1. In Vitro Screening (Figure 2):
Primary Antidiabetic Activities
4.1.1. Assay for Potentiation of Glucose-Stimulated Insulin
Secretion. The pancreas is responsible, primarily through
insulin secretion from beta cells, to respond to elevations in
blood sugar. Pancreatic cell lines such as β-TET cells [58]
can thus be employed to screen extracts for potentiation of
glucose-stimulated insulin secretion (GSIS). These cell lines
release insulin in response to physiological glucose concen-
trations. Changes in secretory properties (basal secretion,
GSIS, and shifts in glucose sensitivity) can be detected by
measuring insulin released into the medium. Hence, this
bioassay can uncover potential insulin secretagogue actions
reminiscent of sulfonylureas. Also, 3H-thymidine incorpo-
ration experiments can be used to uncover eﬀects on beta
cell proliferation [59]. The latter would indicate a potential
for a given plant extract to favor beta cell regeneration and the
replenishment of a functional beta cell mass. Examples of such
eﬀects have been obtained in recent years for antidiabetic
plants such as blueberry [60]a n dN i g e l l a[ 61].
4.1.2. Assay for Potentiation of Glucose Transport. Skeletal
muscle is the main site of glucose disposal in human, and
approximately 80% of total body glucose uptake occurs in
skeletal muscle [62] through insulin- and exercise-sensitive
glucose transporters, Glut4. Following exercise or insulin
stimulation, Glut4 transporters translocate from intracellu-
lar vesicles (basal state) to the cell surface of muscle cells
(and, to a lesser extent, of adipose cells) to mediate glucose
uptake from the bloodstream. Both the insulin-dependent
Akt pathway [10] and insulin-independent exercise pathway
that operates through AMPK [63] can modulate Glut4
translocation. The eﬀects of plant extracts on insulin action
as well as insulinomimetic activity can thus be assessed by
measuring basal- and insulin-stimulated glucose uptake in
(1) the C2C12 skeletal muscle cell line and (2) the 3T3-
L1 adipocyte cell line. Both types of cell lines have been
used as models for insulin-regulated glucose transport for
over 15 years [64–68]. In these lines, insulin-stimulated glu-
cose uptake occurs through the GLUT-4 insulin-responsiveEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: In Vitro screening.
glucose transporter. In addition, such muscle cell lines
also exhibit non-insulin-dependent AMPK-regulated glu-
cose uptake stimulated by metformin, an oral hypoglycemic
of the biguanide class. Hence, these glucose transport assays
can identify insulinomimetic, insulin-sensitizing, or insulin-
independentantidiabeticpotentialatthelevelofskeletalmuscle
or adipose tissue.
4.1.3. Assay for Potentiation of Adipogenesis. As mentioned
above, thiazolidinediones (glitazones) are a valuable class of
antidiabetic drugs that induce an increase in insulin sensi-
tivity by acting on PPAR nuclear receptors and thereby af-
fectingthetranscriptionofanumberofgenesassociatedwith
lipid homeostasis and insulin signal transduction [40]. A
widely used screen for glitazone-like activity involves testing
for the potentiation of adipogenesis in a diﬀerentiating
preadipocyte cell line, such as 3T3-L1 cells, as assessed by en-
hanced accumulation of intracellular triglycerides [69–72].
Rosiglitazone (a reference TZD) serves as a positive control.
In the case of positive adipogenic activity, PPARγ agonism
can be conﬁrmed by a luciferase gene reporter assay [59].
It is also possible that an inhibitory action be uncovered as
happened recently with certain Cree antidiabetic plants [73].
This is not irrelevant since this can represent a potential
antiobesity activity as studied in detail recently [74, 75].
Hence, this bioassay can give insight on the antidiabetic and/or
antiobesity potential of plant preparations on adipose tissue.
4.1.4. Assays for Modulation of Hepatic Glucose Metabolism.
The liver is an insulin-responsive tissue that plays a crucial
role in the homeostasis of glucose by its ability to control
blood sugar level through glucose production or storage, no-
tably in the form of glycogen. This organ also regulates
lipid homeostasis through a process implicating key lipo-
genic enzymes [76]. Finally, the liver plays a prominent role
in T2D, notably through weakened insulin-dependent inhi-
bition of glucose production [77, 78]. Hence, hepatocyte
cell lines, such as the murine H4IIE and human HepG26 Evidence-Based Complementary and Alternative Medicine
hepatoma-derived cells, can serve to measure the eﬀect of
plant preparations on the insulin-dependent and insulin-in-
dependent regulations of hepatic glucose metabolism. Glu-
cose-6-phosphatase catalyses a critical step in gluconeogene-
sis which contributes to enhanced hepatic glucose produc-
tion in T2D [79, 80]. Inhibition of glucose-6-phosphatase
activity thus gives an indication of potential beneﬁcial eﬀect
for T2D. Insulin and metformin can be used as positive con-
trols for inhibition of glucose-6-phosphatase activity. Stim-
ulation of glycogen synthesis from glucose is another way to
reduce hepatic glucose production [81]. The activity of gly-
cogen synthase, the rate-limiting enzyme of glycogen synthe-
sis, can be measured in hepatic cell lines treated with plant
preparations using incorporation of radiolabelled UDP-glu-
cose into glycogen [82]. Treatment with insulin again serves
as a positive control for the stimulation of glycogen synthase.
Hence, these hepatic glucose metabolism assays can help iden-
tify plant preparations that are likely to reduce hepatic glucose
production in vivo, with a corresponding potential to help re-
duce blood glucose in T2D.
4.1.5. Assay for Inhibition of Intestinal Glucose Absorption. A
numberofantidiabeticagentsreduceglycaemiabyinhibiting
digestion and/or absorption of carbohydrates through the
gut.Theseeﬀectsareduetoeitherdirectinteractionwithglu-
cose,therebyinhibiting absorption ofglucosebyenterocytes,
direct inhibition of enterocyte SGLT-1 or GLUT-2 trans-
porters, or inhibition of disaccharidases and other enzymes
of carbohydrate digestion produced by enterocytes (includes
the alpha-glucosidase inhibitor class of oral hypoglycemic
drugsdiscussedabove).Evidencealreadyexistsforinhibition
of digestion and/or absorption of carbohydrates by natural
products [22, 83–85]. Furthermore, there is considerable
interest in inhibitors of SGLT transporters (intestinal and
renal), based on orally active derivatives of phlorizin, as a
novel antidiabetic therapy [86–89]. Intestinal cell lines, such
as CaCo-2 cells, can thus serve to probe plant preparations for
their potential to inhibit intestinal glucose transport and hence
contribute to reducing blood glucose in T2D. This is the ﬁnal
bioassay used in our platform to test for direct antidiabetic
activity.
4.2. In Vitro Screening (Figure 2):
Secondary Antidiabetic Activities
4.2.1. Assay for Cytochrome P450 Inhibition. The cytochrome
P450 (CYP) monooxygenase enzyme systems are responsible
for a large part of xenobiotic metabolism, notably that of
most contemporary pharmaceutical drugs [90]. Plants are
known to contain substances that can interfere with the
normal activity of several CYP enzymes, notably CYPs 3A4,
2C8, 2C9, and 2D6 [91]. Human recombinant CYP enzymes
are commercially available and can be used in vitro to assess
the level of inhibition by natural products contained in plant
preparations, being generally classiﬁed as weak (<30%),
modest (31–75%), or strong (>75%) inhibition [91]. Hence,
this bioassay will give an initial indication of the risk for herb-
druginteractionsforagivenplantpreparation,whichrepresent
a major concern in T2D management.
4.2.2. Assay for Neuroprotective Activity. As mentioned ear-
lier, diabetic neuropathy is one of the major complications
of T2D. This results in good part from the damaging impact
that chronically elevated blood glucose can have on neurons
[92,93].Thissituationcanbereproducedinvitroby subject-
ingpreneuronalorneuronalcellsinculturetohyperglycemic
conditions. For instance, preneuronal PC12 cells subjected
to high glucose concentrations for 96h typically exhibit 40–
50% cell death, which can be prevented by given medicinal
plant preparations [94, 95]. Hence, neuroprotective activity
measured in vitro indicates a good potential for a given
medicinal plant to be beneﬁcial against diabetic neuropathy.
4.2.3. Assay for Antioxidant Activity. As mentioned, T2D
is known to be associated with a state of oxidative stress
[16, 96]. Secondary metabolites serve several functions in
plant physiology such as to protect the plant from damaging
environmental factors, notably oxidative stress [16, 96, 97].
Several of these compounds thus exhibit potent antioxi-
dant properties that have been associated with beneﬁcial
health outcomes in humans, for instance related to the
consumption of fruits and vegetables [98, 99]. There exist
several in vitro, generally cell-free, tests to determine the
antioxidant potential of chemical compounds. Such tests
are not physiologically as relevant as those involving intact
cells or cell lines. Nonetheless, they provide a rapid and
low-cost assessment that is commonly used by academics
and industry researchers alike while even beginning to be
assimilated by the general population. The oxygen radical
absorbance capacity (ORAC) [100] test remains one of
the best-known and most commonly used antioxidant
tests, despite some limitations. Others such as the DPPH
radical scavenging [101] and the thiobarbituric acid reactive
substances (TBARS) assays [102] can also be used. The
strong antioxidant activity of a given medicinal plant will oﬀer
potential beneﬁcial impacts on T2D.
4.2.4. Assay for Antiglycation Activity. When blood glucose
levels remain chronically elevated, covalent interactions
occur between glucose and other blood components, such as
proteins. Indeed, one of the proteins subjected to this type of
glycation is hemoglobin. In fact, glycated hemoglobin, better
known as hemoglobin A1C (Hb-A1C), is used as a reliable
index of chronic hyperglycemia [103]. Moreover, reductions
in the percentage of Hb-1AC present in the blood of T2D
patients are used routinely in the long-term management
of glucose homeostasis (CDA clinical practice guidelines;
[8, 29]). In vitro, it is possible to reproduce the glycation
of proteins by incubating a given substrate (e.g., albumin)
with high concentrations of glucose for a one-week period.
Glycation can then be assessed by ﬂuorometric methods or
by Western blot analysis [104]. Hence, a plant that reduces
protein glycation is likely to exert some beneﬁcial actions in the
context of T2D.
4.2.5. Assay for Anti-Inﬂammatory Activity. Like many
chronic diseases, T2D is also associated with chronic low-
grade inﬂammation [17, 18]. This is related, in part, to the
increased production of proinﬂammatory cytokines such asEvidence-Based Complementary and Alternative Medicine 7
tumor necrosis factor alpha (TNF-alpha). TNF-alpha is also
an adipokine produced in quantities in direct relationship
to the mass of adipose tissue, hence in an elevated manner
in visceral obesity [105]. It is also produced by macrophages
when they are activated by microbial components such as li-
popolysaccharides(LPSs)[106].Hence,astandardcell-based
bioassay used to assess anti-inﬂammatory activity measures
TNF-alpha (or other inﬂammatory cytokines) released by
LPS-activated macrophages in culture put in contact with
the tested agent, in the present case, a given medicinal plant
preparation. Hence, if a medicinal plant exhibits signiﬁcant
anti-inﬂammatory activity, this will represent a potential
beneﬁt in the context of T2D.
4.3. In Vivo Screening (Figures 3 and 4). Biological eﬀects of
plant preparations in primary antidiabetic bioassays should
hold potential to mediate a reduction in blood glucose in
vivo. A number of animal models of obesity and diabetes
exist to evaluate the therapeutic potential of medicinal
plants. Some rely on genetic defects that predispose animals
to obesity (e.g., Ob/Ob mice) or diabetes (e.g., Zucker dia-
betic fatty (ZDF) rats) or chemicals that induce such disor-
ders (e.g., streptozotocin or alloxan). Others use dietary in-
terventions that cause metabolic disturbances in animals
that resemble the spectrum spanning from insulin resistance
to T2D. The CIHR-TAAM has experimented with many of
these models [107, 108], and the diet-induced obesity (DIO)
model in mice has been found to provide stable and reliable
results. This model is illustrated in Figures 3 and 4 and is
brieﬂy described further below.
4.3.1.Diet-InducedObesityMouseModel. ThemaleC57BL/6J
mouse has been considered as a gold standard to generate
the diet-induced obesity (DIO) animal model [109]. This
mouse species develops an obesity phenotype only when
given free access to a high-fat diet whereas individuals
remain normal when fed a low-fat diet (Figure 3). The
weight gain in C57BL/6J mice on the high-fat diet results
from a combination of increased energy intake and de-
creased metabolic rate [110, 111]. In addition to the typical
feature of obesity, C57BL/6J mice on the high-fat diet also
develop insulin resistance, impaired glucose tolerance, mild
to moderate hyperglycemia, dyslipidemia, hypoadiponectin-
emia, leptin resistance/hyperleptinemia, and hypertension
(Figure 4). DIO mice suﬀer from islet dysfunction, decreased
uncoupling protein-2 (UCP2) expression, and downregulat-
ed β3-adrenegic receptor expression and function [112, 113].
The course of diabetes development and the interaction of
nutritional components with genetic variables in C57BL/6J
mouse closely mimic the progression of human diabetes
[114]. Numerous studies have demonstrated that the
C57BL/6J DIO mouse is a suitable animal model for exam-
iningnoveltherapeuticinterventionsandhowdiverseantidi-
abetic drugs exert in vivo eﬃcacy [115, 116]. Therefore, the
DIO mouse model can be used to study the eﬃcacy and
systemic mode of action of medicinal plants on the predia-
betic and early stages of obese T2D. Plant preparations can
be administered to animals in various ways. Intravenous or
intraperitoneal injections are sometimes used, but these do
not reﬂect the oral administration characteristic of the vast
majority of traditional preparations. Gastric gavage using
blunt needles is an eﬃcient way to deliver plant preparations
while respecting precise dosages and administration regi-
mens. However, in small animals like mice, the risk of gastric
puncturesigniﬁcantlyincreaseswiththefrequencyanddura-
tion of plant administration. Moreover, the usual dead vol-
ume of gavage needles can become a barrier, especially when
dealing with more puriﬁed preparations where only small
quantities are often available. It is therefore also common
for plant preparations to be incorporated into either the
drinking water or the feed of laboratory animals. The advan-
tages are that plant preparations can be rather easily and ho-
mogeneously integrated into these matrices. On the other
hand, the dosing requires careful assessment of the amounts
of food and water that are consumed; attention also needs to
be paid to avoid spillage or wastage of food or water in order
to prevent errors in dosing. Nevertheless, such approaches
appropriately mimic oral administration, albeit less so re-
garding dosing frequency, especially in continuous feeders.
Oral feeding/drinking strategies also imply carrying out
initial dosing studies to ﬁnd the optimal range of concen-
trations of plant preparations. It is common to use a dose
of 100mg/kg body weight as a reference starting point for
crude plat extracts, although this does not bear a direct rela-
tionship with a human therapeutic dose. In this instance,
doses of plant preparations in animals, as is also the case for
conventional drugs, cannot easily be translated into human
equivalents.
5. Prioritizing Promising Antidiabetic Plants
Based on TraditionalandScientiﬁc Evidence
The ﬁrst level of prioritization actually relates to the
knowledge of Cree elders and healers. Indeed, the medicinal
plants subjected to scientiﬁc testing need to be identiﬁed
through their use in TM. Ethnobotany is the science that
studies the use of plants and plant-related materials by
human populations for several functions, a major one being
health and wellbeing. Several methods exist to study the
traditional knowledge of human populations, informant
consensus being a common one [117, 118]. However, such
approaches are based on the assumptions that the healers
know the ailment/disease and that they use plants for such
conditions. Since T2D was very rare in Canadian Aboriginal
populations even as recently as 50–60 years ago, a novel
ethnobotanicalapproachwasdevelopedbytheCIHR-TAAM
[117, 118]. This method relies on a set of 15 symptoms
related to T2D. Traditional knowledge holders are asked
about which plant they would use for a given symptom.
Medicinal plant species are then ranked, taking into account
(1) the number of healers that mention a given plant and
(2) the number of symptoms for which the given plant
is used. Results are also weighed according to the impor-
tance/relevance of each symptom to T2D, since some (e.g.,
slow-healing wounds) are quite speciﬁc to T2D while others
(e.g., diarrhea) are not. The result of the algorithm is called a
syndromicimportancevalue(SIV)thatessentiallyrepresents
the antidiabetic potential of a given plant. Seventeen such8 Evidence-Based Complementary and Alternative Medicine
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plantswereprioritizedinthiswayforscientiﬁcassessmentby
the CIHR-TAAM after interviewing 104 Cree elders/healers
in four diﬀerent communities of CEI.
Secondly, from the scientiﬁc point of view, results
from the in vitro bioassay-based screening and the in vivo
assessment of safety and eﬃcacy can be used to rank plants
according to their potential usefulness in the context of T2D.
Table 1 presents a clear example of such a prioritization
exercise using Boreal forest plants from the CIHR-TAAM
project. Plant names have been codiﬁed in order to respect
and preserve the intellectual property rights related to
Aboriginal TM.
InvivoanimalmodelsofobesityandT2Dintegrateallthe
pharmacodynamic (tissue, cellular, and molecular targets)
and pharmacokinetic (absorption, distribution, metabolism,
excretion) elements that will respond to, and impact on,
putative antidiabetic plant preparations. Hence, it is logical
to put a greater priority on positive results obtained in vivo
incomparisontothoseobtainedusinginvitrobioassays.This
explains why results obtained in animals with the various
Boreal forest plants come at the top of the prioritization list
in Table 1. In view of the pathophysiology of T2D discussed
above, the maintenance of normal blood glucose levels is the
primary goal of T2D therapy. Hence, the top outcome toEvidence-Based Complementary and Alternative Medicine 9
Table 1: Prioritization of Boreal forest medicinal plants according to in vivo and in vitro antidiabetic activity.
Plant identiﬁcation
ABCD E F
Elders’ ranking 3 2 1 5
Biological activities related to
primary actions against diabetes Animals Decrease blood glucose   ?
Reduce body weight 
 
?
Reduce fatty liver  ??
Cells Move glucose into muscle cells

  
Reduce glucose produced by liver cells Moderate Moderate
Favour good fat

Moderate

Decrease glucose absorbed from food

 Moderate


Biological activities related to
diabetes complications Cell free Safe to mix with drugs  Moderate  Moderate Moderate 
Fight bad oxygen, bad glucose
  
Cells Fight inﬂammation 




Protect nerves 


Smiley faces: positive eﬀect;

:n oe ﬀect; ?: yet undetermined. The data that forms the basis of this table has been collated from several studies that have
already been published by our team [73–75, 91, 94, 95, 104, 108, 117, 119, 120]a sw e lla sd a t a( e s pe c i a ll yf r o min vivo studies) that have not yet been published
(several currently under review). The names of plants must thus remain undisclosed to protect both the traditional knowledge shared by Cree Elders andt h e
unpublished data.
prioritize in order to identify a plant as potentially antidia-
betic relates to its ability to reduce blood sugar in a diabetic
animal. As also mentioned in the background section, obe-
sity is the single most signiﬁcant determinant of the risk for
T2D. Hence, the second parameter chosen to rank plants
according to their antidiabetic potential relates to a given
plant’s ability to reduce body weight. Thirdly, as discussed
earlier, the ectopic accumulation of fat in the liver plays a sig-
niﬁcant role in the pathophysiology of insulin resistance and
T2D, hence the inclusion of a given plant’s capacity to reduce
hepatic steatosis in the ranking protocol.
Next, results of in vitro bioassays of direct antidiabetic
biologicalactivitycanhelprankplantsaccordingtotheirtar-
get tissue and biological action. As mentioned, skeletal mus-
cle is the single most important tissue for glucose dispos-
al in mammals. Uptake of glucose into muscle cells in culture
was thus chosen as the ﬁrst in vitro parameter to use in the
prioritizationscheme.Cominginaclosesecondisthepoten-
tial for plant preparations to reduce hepatic glucose produc-
tion. That is why the combined eﬀect of a given plant to
inhibitglucose-6-phosphataseandtostimulateglycogensyn-
thase(twokeyenzymescounteringtheproductionofglucose
by the liver) was chosen to rank antidiabetic plants. Next,
favoring the diﬀerentiation of adipocytes is a trait that was
sought in medicinal plant preparations because of the asso-
ciated capacity to store both glucose and free fatty acids
where they are best preserved, to maintain normal glycaemia
and reduce insulin resistance. Finally, inhibition of intestinal
glucose transport in vitro holds promise for potential beneﬁ-
cial action to reduce glucose absorption.
Finally,whatwerecoined“secondaryantidiabeticbiolog-
ical activities” may also be considered when prioritizing me-
dicinal plant species. Both Cree Elders and clinical endocri-
nologists involved in the clinical studies of the CIHR-TAAM
have voiced their concern about using Cree TM alongside
modern pharmaceuticals in the context of T2D. Therefore,
the potential for plants to aﬀect the metabolism of xenobi-
otics, notably drugs, must be taken into consideration since
TM is often taken alongside conventional antidiabetic drugs.
Inhibitory activity against recombinant human cytochromes
P450 was thus included as an important parameter, with the
least inhibition being the desired characteristic of prioritized
medicinal plants. Cytoprotective action, notably towards
cells of neuronal phenotype, is also important to consider in
view of the T2D-associated complication, diabetic neuropa-
thy. Neuroprotective activity was therefore measured and
included as a parameter to rank antidiabetic plants. Last but
not least, antioxidant, antiglycation, and anti-inﬂammatory
activities were selected in view of the known involvement of
oxidative stress and low-grade chronic inﬂammation in T2D.
As can be appreciated from Table 1, several plants of
the Boreal forest that were identiﬁed through the novel
ethnobotanical approach of the CIHR-TAAM exhibit very
interesting combinations of primary and secondary antidi-
abetic activities. This conﬁrms the validity of the ethnob-
otanical method and especially the great wisdom/value of
Aboriginalhealersandtheirtraditionalknowledge.However,
the prioritization scheme presented in Table 1 is based solely
on evidence-based scientiﬁc studies. It was therefore inter-
esting and important to compare the results of this pri-
oritization exercise with the perceptions of Cree Healers
within their Aboriginal worldview and TM paradigm. When
asked to prioritize plants from their TM perspective and to
justify their choice, Cree healers spoke of their respect for
a given plant and shared healing experiences that they had
or witnessed with the same plant. Their prioritization was
thus much more grounded in the spiritual realm, in person-
al experience, and natural laws. Notwithstanding how diﬀer-
ent the two worldviews can be, the most striking outcome
was that the majority of plants ranking among the most10 Evidence-Based Complementary and Alternative Medicine
promising antidiabetic plants, as prioritized by the scientiﬁc
approach, were the same as those held to the greatest es-
teem by Cree healers, 4 out of 6. This speaks highly for a
convergence of health parameters across cultural barriers.
Instead of “validating” Cree TM (which may be seen as car-
rying negative connotations, especially from the Aboriginal
TM perspective), the work of the CIHR-TAAM may rather
ﬁnd its value and usefulness in “translating” Aboriginal tra-
ditional knowledge into the language of evidence-based sci-
ence that health authorities can better appreciate.
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